69763-40-2

Upstream product

• 1285574-25-5 1-cyclobutyl-2-(methoxymethoxy)benzene 
• 68314-54-5 1-bromo-2-(methoxymethoxy)benzene 
• 95-56-7 2-hydroxybromobenzene 

Downstream Products

• 1285574-26-6 3-cyclobutyl-2-hydroxybenzaldehyde 
• 1285574-28-8 5-bromo-3-cyclobutyl-2-hydroxybenzaldehyde 
• 1285574-31-3 5-bromo-3-cyclobutyl-2-methoxybenzaldehyde 
• 1285574-33-5 5-bromo-3-cyclobutyl-1-diethoxymethyl-2-methoxybenzene 
• 1285574-35-7 3-cyclobutyl-5-formyl-4-methoxybenzoic acid 
• 1285574-36-8 3-cyano-5-cyclobutyl-4-methoxybenzoic acid 
• 1285574-37-9 3-cyano-5-cyclobutyl-4-methoxybenzoyl chloride 
• 1285574-39-1 3-(3-cyano-5-cyclobutyl-4-methoxybenzoyl)-2,3-dihydro-1,3-benzothiazole 
• 1285574-41-5 3-(3-cyano-5-cyclobutyl-4-methoxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285572-69-1 3-(3-cyano-5-cyclobutyl-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1402001-81-3 2-[2-(2-cyclobutylphenoxy)ethyl]-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione 
• 1285574-25-5 1-cyclobutyl-2-(methoxymethoxy)benzene 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion chann

Compounds For The Treatment Of Neuromuscular Disorders

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.

HETEROCYCLIC COMPOUND

Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND

[Problem] On the basis of a cathepsin S inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. [Means for Solution] It was found that a nitrogen-containing bicyclic heterocyclic compound has the excellent cathepsin S inhibitory effect, thereby completing the invention. The compound of the present invention has the cathepsin S inhibitory effect, and can be used as an agent for preventing and/or treating autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like.

Substrate-Based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase

High levels of striatal-enriched protein tyrosine phosphatase (STEP) activity are observed in a number of neuropsychiatric disorders such as Alzheimer's disease. Overexpression of STEP results in the dephosphorylation and inactivation of many key neuronal